At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo Controlled, Pilot Trial of Statin Use in Burn Patients
In Brief
A Phase 2 clinical trial evaluating Rosuvastatin and Placebo for Burns. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to 28 days. The study will assess the affect of statins administered soon after burn injury on C-reactive protein (CRP) levels, patient mortality and the incidence of septic shock. The investigators also seek to describe the correlation between exposure to statins and development of delirium and de-novo long-term cognitive impairment. Hypothesis: 1. Statin administration within 96 hours of burn is safe, will decrease CRP, and will decrease septic shock and mortality in burn patients. 2. The investigators hypothesize that burn patients will have a de-novo long term cognitive impairment at 3 months after burn. 3. The investigators hypothesize the use of statins in burn patients will reduce the development and the degree of cognitive impairment at 3 months post burn.
Study Details
Timeline
Interventions
Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
Placebo administered every day for up to 28 days